source
- REVELUTION-2 trial assesses cardiovascular safety of relugolix plus abiraterone in high‑risk prostate cancerThe REVELUTION-2 study is focused on measuring the heart‑related risks associated with a hormone‑therapy regimen that combines relugolix and abiraterone acetate in patients with high‑risk prostate…
- TROP2 scoring and MTAP loss emerge as key biomarkers for NSCLC treatment decisionsResearchers are highlighting two molecular features-TROP2 expression and loss of the MTAP enzyme-as potential guides for therapy in non‑small cell lung cancer. Quantitative scoring of TROP2 by pat…